Search
Search
Carl D. Regillo, MD, FACS, David A. Eichenbaum, MD, and Anat Loewenstein, MD, MHA
Show Description +
Carl D. Regillo, MD, FACS; Anat Loewenstein, MD, MHA; and David A. Eichenbaum, MD; dispel myths surrounding compliance with topical treatments for diabetic retinopathy. Dr. Loewenstein shares how she educates patients about using a less invasive topical drug. Dr. Eichenbaum highlights how such medications can help reduce the burden of the disease and delay progression with safe and effective treatment options.
Posted: 9/06/2023
Carl D. Regillo, MD, FACS, David A. Eichenbaum, MD, and Anat Loewenstein, MD, MHA
Carl D. Regillo, MD, FACS; Anat Loewenstein, MD, MHA; and David A. Eichenbaum, MD; dispel myths surrounding compliance with topical treatments for diabetic retinopathy. Dr. Loewenstein shares how she educates patients about using a less invasive topical drug. Dr. Eichenbaum highlights how such medications can help reduce the burden of the disease and delay progression with safe and effective treatment options.
Posted: 9/06/2023
Current Practice and Future Options for Nonproliferative Diabetic Retinopathy
DR Research Roundup: Phase 2 and 3
Shifting the Paradigm
Current Practice and Future Options for Nonproliferative Diabetic Retinopathy
To find out more about the phase 2 DREAM study of OTT166 in eyes with diabetic retinopathy and how you can refer your patients, please contact the representative from Parexel, the CRO assisting OcuTerra in facilitating the DREAM study, listed below.
Learn MoreAbout Ocuterra
OcuTerra is led by a team with significant biotechnology entrepreneurial and ophthalmology drug development experience and supported by the field’s leading scientific and clinical advisors.
Visit us online: ocuterratx.com
Follow Ocuterra
© 2023 OcuTerra Therapeutics, Inc.
